Covid19-Sources

Learn how SARS-CoV-2 infection is categorized by severity of illness.

It is not normal for young athletes to suffer cardiac arrest or death while playing sport, but most of these come shortly after a COVID shot.

Dozens of prominent athletes did not die of heart attacks after COVID-19 vaccination

On Jan 6, 2022, the UK Government's Office of National Statistics (ONS) published their latest report on the prevalence of long COVID in the UK from a representative survey. As of Dec 6, 2021, around 1·266 million people living in the UK had self-reported long COVID (95% CI 1·228–1·304; 2% of the total population), defined as symptoms persisting for more than 4 weeks after the first confirmed or suspected COVID-19 infection. Of these individuals, 892 000 (70%) had confirmed or suspected COVID-19 at least 12 weeks previously.

Viral infections are a common cause of myocarditis. Some studies have indicated an association between COVID-19 and myocarditis.

Long COVID umfasst Symptome, die nach einer akuten COVID-19-Erkrankung neu auftreten und Wochen oder Monate nach Erkrankungsbeginn anhalten. Die Symptome können mit der Zeit abklingen oder sich zu einem anhaltenden Beschwerdebild entwickeln, das mit einer starken Einschränkung der Lebensqualität einhergeht. Eine Subgruppe von Menschen mit Long COVID hat eine große…

Characteristics of people testing positive for COVID-19 from the Coronavirus (COVID-19) Infection Survey.

Results from a study of 19 deceased patients suggests brain damage is a byproduct of a patient’s illness.

This systematic review and meta-analysis investigates the frequency of adverse events in placebo groups compared with that in vaccine groups in COVID-19 vaccine trials.

Are on the rise. But is it Omicron, or "Omicron"?

3/4 der Impfreaktionen/Nebenwirkungen eingebildet?Laut einer Untersuchung der Harvard Uni sind bis zu 76% der den Körper betreffenden Reaktionen nach Erst-Impfung und 52% der gemeldeten Folgen nach der 2. Impfdosis dem sogenannten „Nozebo“ (analog Plazebo) Effekt zuzuschreiben! pic.twitter.com/eoaKdIlxxu— OrthopaeDenker (@dokhollidays) January 20, 2022

Valneva Reports Positive Phase 3 Results for Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001 that successfully met both co-primary endpoints. Superio

In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most count…

The new SARS-CoV-2 variant of concern “Omicron” was recently (Nov. 24th. 2021) spotted in South Africa and already spread around the world due to its enhanced transmissibility. The variant became conspicuous as it harbors more than thirty mutations in the spike protein with 15 mutations in the RBD region alone, potentially dampening the potency of therapeutic antibodies and enhancing the ACE2 binding. More worrying, Omicron infections have been reported in individuals who have received vaccines jabs in South Africa and Hong Kong. Here, we investigated the binding strength of Omicron with ACE2 and seven monoclonal antibodies that are either approved by FDA for COVID-19 therapy or undergoing phase III clinical trials. Computational mutagenesis and binding free energies could confirm that Omicron Spike binds ACE2 stronger than prototype SARS-CoV-2. Notably, three substitutions, i.e., T478K, Q493K, and Q498R, significantly contribute to the binding energies and doubled electrostatic potential of the RBDOmic-ACE2 complex. Instead of E484K substitution that helped neutralization escape of Beta, Gamma, and Mu variants, Omicron harbors E484A substitution. Together, T478K, Q493K, Q498R, and E484A substitutions contribute to a significant drop in the electrostatic potential energies between RBDOmic-mAbs, particularly in Etesevimab, Bamlanivimab, and CT-p59. CDR diversification could help regain the neutralization strength of these antibodies; however, we could not conduct this analysis to this end. Conclusively, our findings suggest that Omicron binds ACE2 with greater affinity, enhancing its infectivity and transmissibility. Mutations in the Spike are prudently devised by the virus that enhances the receptor binding and weakens the mAbs binding to escape the immune response. ### Competing Interest Statement The authors have declared no competing interest.

Ich danke allen, die sich dafür einsetzen, dass wir mehr über #LongCovid und #PostCovid erfahren!Auch wenn wir noch nicht genau wissen in welcher Häufigkeit mit #Langzeitfolgen zu rechnen ist:Wir müssen wohl auch bei Kindern von 2% ausgehen!https://t.co/1NvJgKodWo👇 pic.twitter.com/3ISRAEitTz— Amelie Thobaben (@AThobaben) August 17, 2021

Prophezeiungen, Prognosen, Vorhersagungen und Zukunftsgedanken der Querdenker ab September 2021 mit Bodo Schiffmann, Michael Ballweg, Attila Hildmann, ...

This report has been published to share the detailed variant surveillance analyses which contribute to the variant risk assessments and designation of new variants of concern (VOC) and variants under investigation (VUI). This specialist technical briefing contains early data and analysis on emerging variants and findings have a high level of uncertainty.

Background: Long COVID is a post-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection syndrome characterised by not recovering for several weeks or months following the acute episode. The effectiveness of COVID-19 vaccines against long-term symptoms of COVID-19 is not well understood. We determined whether vaccination was associated with the incidence of reporting long-term symptoms post-SARS-CoV-2 infection Methods: We invited individuals who were PCR tested for SARS-CoV-2 infection at participating hospitals between March 2020-November 2021 to fill an online questionnaire that included baseline demographics, details of their acute episode and information about symptoms they were currently experiencing. Using binomial regression, we compared vaccinated individuals with those unvaccinated and those uninfected in terms of self-reported symptoms post-acute infection. Results: We included 951 infected and 2437 uninfected individuals. Of the infected, 637(67%) were vaccinated. The most commonly reported symptoms were; fatigue (22%), headache (20%), weakness (13%), and persistent muscle pain (10%). After adjusting for follow-up time and baseline symptoms, those who received two doses less likely than unvaccinated individuals to report any of these symptoms by 64%, 54%, 57%, and 68% respectively, (Risk ratios 0.36, 0.46, 0.43, 0.32, p

Patients who survive coronavirus disease 2019 (COVID-19) are at higher risk of post-acute sequelae involving pulmonary and several extrapulmonary organ systems—generally referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. Here we show that, beyond the acute phase of illness, 30-day survivors of COVID-19 exhibited higher risks of AKI, eGFR decline, ESKD, major adverse kidney events (MAKE), and steeper longitudinal decline in eGFR. The risks of kidney outcomes increased according to the severity of the acute infection (categorized by care setting into non-hospitalized, hospitalized, and admitted to intensive care). The findings provide insight into the long-term consequences of COVID-19 on kidney outcomes and suggest that post-acute COVID-19 care should include attention to kidney function and disease. Background COVID-19 is associated with increased risk of post-acute sequelae involving pulmonary and extrapulmonary organ systems—referred to as long COVID. However, a detailed assessment of kidney outcomes in long COVID is not yet available. Methods We built a cohort of 1,726,683 US Veterans identified from March 1, 2020 to March 15, 2021, including 89,216 patients who were 30-day survivors of COVID-19 and 1,637,467 non-infected controls. We examined risks of AKI, eGFR decline, ESKD, and major adverse kidney events (MAKE). MAKE was defined as eGFR decline ≥50%, ESKD, or all-cause mortality. We used inverse probability–weighted survival regression, adjusting for predefined demographic and health characteristics, and algorithmically selected high-dimensional covariates, including diagnoses, medications, and laboratory tests. Linear mixed models characterized intra-individual eGFR trajectory. Results Beyond the acute illness, 30-day survivors of COVID-19 exhibited a higher risk of AKI (aHR, 1.94; 95% CI, 1.86 to 2.04), eGFR decline ≥30% (aHR, 1.25; 95% CI, 1.14 to 1.37), eGFR decline ≥40% (aHR, 1.44; 95% CI, 1.37 to 1.51), eGFR decline ≥50% (aHR, 1.62; 95% CI, 1.51 to 1.74), ESKD (aHR, 2.96; 95% CI, 2.49 to 3.51), and MAKE (aHR, 1.66; 95% CI, 1.58 to 1.74). Increase in risks of post-acute kidney outcomes was graded according to the severity of the acute infection (whether patients were non-hospitalized, hospitalized, or admitted to intensive care). Compared with non-infected controls, 30-day survivors of COVID-19 exhibited excess eGFR decline (95% CI) of −3.26 (−3.58 to −2.94), −5.20 (−6.24 to −4.16), and −7.69 (−8.27 to −7.12) ml/min per 1.73 m2 per year, respectively, in non-hospitalized, hospitalized, and those admitted to intensive care during the acute phase of COVID-19 infection. Conclusions Patients who survived COVID-19 exhibited increased risk of kidney outcomes in the post-acute phase of the disease. Post-acute COVID-19 care should include attention to kidney disease.

Whoa—New study found active #SARSCoV2 in the intestines of children for up to 36 days—70% of infected children carried the active virus without showing any symptoms, giving worry to “invisible transmitters”. Of 22 cases, 20 were children under age of 6. 🧵https://t.co/r8cuyZECII pic.twitter.com/uaVc7MWSTJ— Eric Feigl-Ding (@DrEricDing) April 6, 2021

Nature - Despite evidence that pregnant people are at high risk of serious disease, many remain unvaccinated.

Four coronavirus (COVID-19) vaccines have now been approved for use in the UK. Rigorous clinical trials have been undertaken to understand the immune response, safety profile and efficacy of these vaccines as part of the regulatory process. Ongoing monitoring of the vaccines as they are rolled out in the population is important to continually ensure that clinical and public health guidance on the vaccination programme is built upon the best available evidence. UK Health Security Agency (UKHSA), formerly Public Health England (PHE), works closely with the Medicines and Healthcare Regulatory Agency (MHRA), NHS England, and other government, devolved administration and academic partners to monitor the COVID-19 vaccination programme. Details of the vaccine surveillance strategy are set on the page COVID-19: vaccine surveillance strategy (1). As with all vaccines, the safety of COVID-19 vaccines is continuously being monitored by the MHRA. They conclude that overall, the benefits of COVID-19 vaccines outweigh any potential risks (2).

Comirnaty (BNT162b2) Erstversion 01/2021; zuletzt aktualisiert 12/2021 Ich werde als Ärztin immer wieder gefragt, ob ich etwas zu der Covid-19-Impfung sagen kann. Und zugegeben, als Assistenzärztin für Anästhesie (aktuell auf einer Intensivstation), bin ich zwar nicht unbedingt prädestiniert, über alle notwendigen Infos dieser Thematik zu verfügen, aber, nachdem ich schon vieles auf Social Media Kanälen lesen musste, habe ich versucht, die Fakten […]

Die Inzidenz ist hoch wie nie. Doch der Coronavirus-Experte Christian Drosten von der Charité Berlin macht Hoffnung: Das Änderungspotenzial von Sars-Cov-2 ist grundsätzlich begrenzt, sagt er.

Correspondence from The New England Journal of Medicine — Severity of SARS-CoV-2 Reinfections as Compared with Primary Infections

Survivors of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection frequently experience lingering neurological symptoms, including impairment in attention, concentration, speed of information processing and memory. This long-COVID cognitive syndrome shares many features with the syndrome of cancer therapy-related cognitive impairment (CRCI). Neuroinflammation, particularly microglial reactivity and consequent dysregulation of hippocampal neurogenesis and oligodendrocyte lineage cells, is central to CRCI. We hypothesized that similar cellular mechanisms may contribute to the persistent neurological symptoms associated with even mild SARS-CoV-2 respiratory infection. Here, we explored neuroinflammation caused by mild respiratory SARS-CoV-2 infection – without neuroinvasion - and effects on hippocampal neurogenesis and the oligodendroglial lineage. Using a mouse model of mild respiratory SARS-CoV-2 infection induced by intranasal SARS-CoV-2 delivery, we found white matter-selective microglial reactivity, a pattern observed in CRCI. Human brain tissue from 9 individuals with COVID-19 or SARS-CoV-2 infection exhibits the same pattern of prominent white matter-selective microglial reactivity. In mice, pro-inflammatory CSF cytokines/chemokines were elevated for at least 7-weeks post-infection; among the chemokines demonstrating persistent elevation is CCL11, which is associated with impairments in neurogenesis and cognitive function. Humans experiencing long-COVID with cognitive symptoms (48 subjects) similarly demonstrate elevated CCL11 levels compared to those with long-COVID who lack cognitive symptoms (15 subjects). Impaired hippocampal neurogenesis, decreased oligodendrocytes and myelin loss in subcortical white matter were evident at 1 week, and persisted until at least 7 weeks, following mild respiratory SARS-CoV-2 infection in mice. Taken together, the findings presented here illustrate striking similarities between neuropathophysiology after cancer therapy and after SARS-CoV-2 infection, and elucidate cellular deficits that may contribute to lasting neurological symptoms following even mild SARS-CoV-2 infection. ### Competing Interest Statement A.I. served as a consultant for Spring Discovery, Boehringer Ingelheim and Adaptive Biotechnologies. I.Y. reports being a member of the mRNA-1273 Study Group and has received funding to her institution to conduct clinical research from BioFire, MedImmune, Regeneron, PaxVax, Pfizer, GlaxoSmithKline, Merck, Novavax, Sanofi-Pasteur and Micron. M.M. serves in the scientific advisory board of Cygnal Therapeutics.

This study examines insurer coverage of ivermectin prescriptions for COVID-19 in the US.

Schwere Verläufe von COVID-19 können nun frühzeitig entdeckt werden. Forschende der Universität Zürich haben den ersten Biomarker identifiziert, der zuverlässige Voraussagen ermöglicht. Patienten mit schweren Krankheitsverläufen können so bestmöglich versorgt werden.

Background The Omicron SARS-CoV-2 variant is responsible for a major wave of COVID-19, with record case counts reflecting high transmissibility and escape from prior immunity. Defining the time course of Omicron viral proliferation and clearance is crucial to inform isolation protocols aiming to minimize disease spread. Methods We obtained longitudinal, quantitative RT-qPCR test results using combined anterior nares and oropharyngeal samples (n = 10,324) collected between July 5th, 2021 and January 10th, 2022 from the National Basketball Association’s (NBA) occupational health program. We quantified the fraction of tests with PCR cycle threshold (Ct) values

Patients were enrolled from May 5, 2020, until Jan 27, 2021. 528 patients were screened, of whom 520 were randomly assigned and included in the intention-to-treat population. 479 of these patients (n=236, lenzilumab; n=243, placebo) were included in the mITT analysis for the primary outcome. Baseline demographics were similar between groups. 311 (65%) participants were males, mean age was 61 (SD 14) years at baseline, and median C-reactive protein concentration was 79 (IQR 41–137) mg/L. Steroids were administered to 449 (94%) patients and remdesivir to 347 (72%) patients; 331 (69%) patients received both treatments. Survival without invasive mechanical ventilation to day 28 was achieved in 198 (84%; 95% CI 79–89) participants in the lenzilumab group and in 190 (78%; 72–83) patients in the placebo group, and the likelihood of survival was greater with lenzilumab than placebo (hazard ratio 1·54; 95% CI 1·02–2·32; p=0·040). 68 (27%) of 255 patients in the lenzilumab group and 84 (33%) of 257 patients in the placebo group experienced at least one adverse event that was at least grade 3 in severity based on CTCAE criteria. The most common treatment-emergent adverse events of grade 3 or higher were related to respiratory disorders (26%) and cardiac disorders (6%) and none led to death. Interpretation Lenzilumab significantly improved survival without invasive mechanical ventilation in hospitalised patients with COVID-19, with a safety profile similar to that of placebo. The added value of lenzilumab beyond other immunomodulators used to treat COVID-19 alongside steroids remains unknown.